Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer

Background Peritoneal carcinomatosis in ovarian cancer is frequent and generally associated with higher stage and poorer outcome. The clinical features of peritoneal carcinomatosis are diverse and their relevance for surgical and long-term outcome remains unclear. We conducted this prospective study to describe intraoperatively the different features of peritoneal carcinomatosis(PC) and correlate them with clinicopathological features, progression-free(PFS) and overall survival (OS),. Methods We performed a systematic analysis of all patients with documented intraoperative PC and a primary diagnosis of epithelial ovarian, tubal, or peritoneal cancer from January 2001 to September 2018. All data were evaluated by using the systematic tumor bank tool. Specific PC features included texture(soft-hard), consistency(coarse-fine or both), wet vs dry(PC with ascites vs. PC without ascites), and localization(diffuse-local). PC characteristics were then evaluated for correlation with age, FIGO-stage, histology, lymph-node involvement, grade, and presence of residual tumor at primary surgery. Moreover, the influence of PC characteristics on OS and PFS was analyzed. Results A total of 1686 patients with PC and primary epithelial ovarian cancer were included. Majority of the patients were characterized by diffuse PC(73.9%). The majority of peritoneal nodules were fine in texture (55.3%) and hard in consistency (87.4%). Moreover, 27.6% of patients had dry PC. Diffuse PC localization was significantly associated with higher FIGO-stage (p<0.001), high-grade (p=0.003) and serous tumors (p=0.006) as well as residual tumor as compared to local PC (p<0.001). Wet PC also significantly correlated with diffuse localization (p <0.001) and residual tumor as compared to dry PC (p<0.001). Coarse PC was significantly associated with residual tumor as compared to fine PC (p=0.044). All other PC features didn´t correlate with clinicopathological features. As for survival outcomes, diffuse peritoneal localization (p<0.001), wet PC (p<0.001), and additional lymph node involvement (p<0.001) were associated with lower OS and PFS rates. Other PC features did not significantly impact survival. Conclusion Diffuse localization of peritoneal carcinomatosis was significant predictor of recurrence. Lower OS and PFS were associated with diffuse peritoneal localization, wet PC, and additional lymph node involvement. Further prospective trials are warranted with the inclusion of translational research aspects to better understand the different peritoneal carcinomatosis patterns.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[4]  K. Stålberg,et al.  The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer , 2020, Annals of Surgical Oncology.

[5]  Wei Zhang,et al.  The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment , 2020, Medicine.

[6]  J. Sehouli,et al.  Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer , 2019, International Journal of Gynecological Cancer.

[7]  T. Chua,et al.  Intraoperative macroscopic tumour consistency is associated with overall survival after cytoreductive surgery and intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases: A retrospective observational study. , 2019, American journal of surgery.

[8]  Jae-Weon Kim,et al.  A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms , 2019, The New England journal of medicine.

[9]  A. Bhatt,et al.  Correlation Between Pelvic Peritoneal Disease and Nodal Metastasis in Advanced Ovarian Cancer: Can Intraoperative Findings Define the Need for Systematic Nodal Dissection? , 2019, Indian Journal of Surgical Oncology.

[10]  Ting Yu,et al.  A retrospective clinical study , 2021 .

[11]  J. Esquivel,et al.  2017 Update on Ovarian Cancer Peritoneal Carcinomatosis Multimodal-Treatment Considerations , 2018, Gastroenterology research and practice.

[12]  G. Kenter,et al.  Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review , 2018, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[13]  Jaime Prat,et al.  FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication , 2015, Journal of gynecologic oncology.

[14]  P. Piso,et al.  Prognostic Significance of Sugarbaker’s Peritoneal Cancer Index for the Operability of Ovarian Carcinoma , 2015, International Journal of Gynecologic Cancer.

[15]  J. Sehouli,et al.  Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer , 2015, Annals of Surgical Oncology.

[16]  J. Magrina,et al.  Correlation between the extent of intraperitoneal disease and nodal metastasis in node-positive ovarian cancer patients. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  R. Zeillinger,et al.  Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data , 2012, International Journal of Gynecologic Cancer.

[18]  J. Magrina,et al.  The Impact of Peritoneal Metastases in Epithelial Ovarian Cancer With Positive Nodes , 2011, International Journal of Gynecologic Cancer.

[19]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[20]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[21]  J. Muntané,et al.  Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[22]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[23]  The International Consortium for Outcome Research in H Cancer The general rules for the gastric cancer study in surgery and pathology , 2006, The Japanese journal of surgery.

[24]  H. van Tinteren,et al.  Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy , 2004, The British journal of surgery.

[25]  R. Rouzier,et al.  Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. , 2003, Journal of the American College of Surgeons.

[26]  W. Lichtenegger,et al.  „IMO” - Intraoperatives Mapping des Ovarialkarzinoms , 2003 .

[27]  L. Weiss Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells. , 1996, Cancer treatment and research.

[28]  K. Jablonski,et al.  Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.

[29]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[30]  Tanaki Kajitani,et al.  The general rules for the gastric cancer study in surgery and pathology , 1981, The Japanese journal of surgery.

[31]  M. A. Meyers DISTRIBUTION OF INTRA-ABDOMINAL MALIGNANT SEEDING: DEPENDENCY ON DYNAMICS OF FLOW OF ASCITIC FLUID , 1973 .

[32]  M. A. Meyers Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. , 1973, The American journal of roentgenology, radium therapy, and nuclear medicine.